The American Diabetes Association (ADA)/European Association for the Study of Diabetes (EASD) issued guidelines recommending long-acting insulin for patients with HbA1C > 7.0% after treatment with two oral antidiabetic drugs (OADs). The gene discussed is INS; the disease is diabetes mellitus.